Concepedia

Wendy De Roock

WD

Statistics

Publications

24

Citations

5.3K

H-Index

18

Active since

2007

Affiliations

KU Leuven(Current)

Cliniques Universitaires Saint-Luc

Ziekenhuis Oost-Limburg

Ghent University Hospital

Aristotle University of Thessaloniki

Wendy De Roock is an author at KU Leuven specializing in oncology, medicine, and colorectal cancer.

Publications per year

2007–2024

24

Publications

24

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

Wendy De Roock, Hubert Piessevaux, Joris De Schutter et al. · Annals of Oncology · 2007 · 827 citations · Full text

Medicine, Oncology, Radiology +12

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio et al. · JAMA · 2010 · 747 citations

Medicine, Oncology, Pharmacology +17

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

Bart Jacobs, Wendy De Roock, Hubert Piessevaux et al. · Journal of Clinical Oncology · 2009 · 368 citations · Full text

Medicine, Oncology, Pharmacology +17

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Hans Prenen, Jef De Schutter, Bart Jacobs et al. · Clinical Cancer Research · 2009 · 293 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 24